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SHORT PAPER
David S. Miller: Scientist, Mentor, Friend—a 
tribute and thank you
Björn Bauer1* , J. Larry Renfro2, Karl J. Karnaky Jr.3, Rosalinde Masereeuw4, Gert Fricker5, Ron E. Cannon6 
and Anika M. S. Hartz7,8
Abstract 
David S. Miller was Acting Scientific Director of the Division of Intramural Research at the National Institute of Environ‑
mental Health Sciences, National Institutes of Health, and Head of the Intracellular Regulation Group in the Laboratory 
of Toxicology and Pharmacology before he retired in 2016. David received his Ph.D. in biochemistry from the Univer‑
sity of Maine in 1973. David was a Group Leader at the Michigan Cancer Foundation before joining the NIEHS in 1985. 
His research covered a wide range from renal excretory transport mechanisms to regulation of transporters at the 
blood–CSF and blood–brain barriers, from fish, amphibians and birds to mammals. David was an outstanding scientist 
with irresistible enthusiasm for science and an incredible ability to think outside the box while being an exceptional 
mentor and friend.
© The Author(s) 2020. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, 
adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and 
the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material 
in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material 
is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the 
permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creat iveco 
mmons .org/licen ses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creat iveco mmons .org/publi cdoma in/
zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Introduction
David S. Miller’s research career maintained a central 
theme of understanding how the body protects itself 
from toxic chemicals. This line of research was initiated 
during his graduate studies where he characterized the 
transport of toxic molecules, which evolved into stud-
ies on solute transport in various model systems. In the 
mid-1970s, David’s work in Dr. William B. Kinter’s labo-
ratory linked the thinning of duck eggshells to expo-
sure to the pesticides dichloro-diphenyltrichloroethane 
(DDT) and dichlorodiphenyldichloroethylene (DDE) [1, 
2]. To understand how the body protects and removes 
toxic molecules led David to first investigate transporters 
in fish, crabs, and sea birds. In 1985, David was recruited 
to the National Institute of Environmental Health Sci-
ences (NIEHS), National Institutes of Health (NIH) as an 
Expert Research Physiologist in the Laboratory of Cellu-
lar and Molecular Pharmacology. Here, David and John 
Pritchard resumed their scientific collaboration, begun 
in the early 1970s at the Mount Desert Island Biological 
Laboratory (MDIBL), that would continue for the rest 
of their careers. In their studies, David and John uti-
lized different species including teleosts, Xenopus laevis, 
crabs, flounder, rats and mice and various model sys-
tems including oocytes, renal proximal tubules, isolated 
membrane vesicles and isolated brain capillaries. Their 
collaborative research focused on organic anions and 
cations and led to the major discovery that anion trans-
port was coupled to the membrane potential through 
dicarboxylate exchange (mostly α-ketoglutarate) afforded 
by the electrogenic, sodium/potassium ATPase pump [3]. 
Throughout the 1990s, David continued to investigate the 
regulation of organic anion transport in Xenopus oocytes 
and fish kidneys using killifish as a model organism. In 
the late 1990s, his interest shifted toward transport pro-
cesses in the blood-CSF barrier (choroid plexus) and 
the blood–brain barrier. David recognized that confocal 
microscopy had immense value for studying transport 
processes and the confocal microscope became an inte-
gral tool in his research. By the early 2000s, researchers 
had identified and cloned numerous ABC transporters 
including David’s three favorites: P-glycoprotein (P-gp, 
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MDR1, ABCB1), breast cancer resistance protein (BCRP, 
ABCG2), and multidrug resistance-associated protein 
2 (MRP-2, ABCC2). David dedicated the final years of 
his career to identify intracellular signaling pathways 
responsible for the regulation of these transporters at the 
blood–brain barrier and contributed several seminal dis-
coveries to the field.
Main text
Education, career, and scientific contribution at a glance
David Samuel Miller was born on July 24, 1945 in Brook-
lyn, New York City and attended Abraham Lincoln High 
School in Brooklyn, NY (Fig. 1a). In 1966, David received 
his BS in Chemistry from the Brooklyn College, Brook-
lyn, New York. From 1967 until 1970, David pursued 
graduate studies in physical organic chemistry at the City 
University of New York. Shortly after, David joined Dr. 
Joseph Lerner’s laboratory at the University of Maine, 
Orono, Maine, as a Ph.D. student. During his thesis work, 
David also attended seminars at the Mount Desert Island 
Biological Laboratory (MDIBL), Salsbury Cove, Maine, 
where he was introduced to John Pritchard, who was a 
MDIBL post-doctoral fellow at that time. David obtained 
his Ph.D. in Biochemistry from the University of Maine in 
1973 and accepted a post-doctoral position at MDIBL in 
the laboratory of Dr. William B. Kinter. From 1976–1978, 
David continued at MDIBL as an Associate Research Sci-
entist and then from 1978–1981 as a Research Scientist 
(Fig. 1b–d). During this time, David met Joseph Fenster-
macher, who worked on the diffusion of molecules within 
the brain extracellular space and blood–brain barrier 
properties in health and disease [4]. In 1981, David joined 
the Michigan Cancer Foundation in Detroit, MI as an 
Assistant Member in the Department of Physiology and 
Biophysics. He became Chief of the Laboratory of Meta-
bolic Control in 1982. In 1985, John Pritchard recruited 
David to the NIEHS as an Expert Research Physiologist 
in the Laboratory of Cellular and Molecular Pharmacol-
ogy working under Martin Rodbell, a 1994 Nobel Lau-
reate in Physiology or Medicine. At the NIEHS, David 
advanced his scientific career and became PI and Head 
of the Intracellular Regulation Group in 1988, Chief of 
the Laboratory of Toxicology and Pharmacology and 
Director of the Environmental Toxicology Program in 
2010, and ultimately served as the NIEHS Acting Scien-
tific Director of Intramural Research 2010–2011 (Fig. 1e). 
David remained Senior Investigator and Head of the 
Intracellular Regulation Group until he officially retired 
in 2016.
Scientific career—from chickens to regulatory pathways 
at the blood–brain barrier
Postdoctoral work until mid‑1990s
Early post‑doctoral and  research scientist years 
at the Mount Desert Island Biological Laboratory Notes 
from Larry Renfro: David joined the Kinter laboratory at 
MDIBL in 1973 as a postdoc, the year before I moved to 
the University of Connecticut, but that overlap was suf-
ficient to cement a career long respect for and interac-
tion with him [5–9]. David’s biochemistry background 
coupled with the amino acid transport work that he and 
Lerner did at the University of Maine prepared him per-
Fig. 1 David S. Miller. a David S. Miller in 2010. b David in his laboratory at the MDIBL. c Mount Desert Island Biological Laboratory, MDIBL, Salsbury 
Cove, Maine. d Door sign on David’s laboratory at the MDIBL. e David giving a presentation entitled “How Therapeutic Drugs and Nasty Chemicals 
Move Around Your Body (The good, the bad and the ugly)” as part of the NIEHS “Big Picture, Small Talk” seminar series December 9, 2014 (Courtesy Steve 
McCaw and David Miller; https ://facto r.niehs .nih.gov/2015/1/insid e‑bigpi cture /index .htm)
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fectly for work with the Kinter group. As a result, he had 
an impressively productive post-doctoral period, foretell-
ing the superb contributions in all the later years.
With William Kinter and David Peakall, David pro-
duced several papers on eggshell thinning in duck, 
including two Nature papers and one in Science [1, 2, 
10–12]. Toxicity of the pesticide dichloro-diphenyl-
trichloroethane (DDT) to humans and animals was 
beginning to be understood by the mid-1940s. Subse-
quently, effects of DDT/DDE (dichlorodiphenyldichlo-
roethylene) were directly linked to population declines 
in certain avian species, especially the raptors. Stickel’s 
1975 [13] assertion that DDE was a potent inhibitor of 
eggshell thinning remains accurate today, and the under-
lying cause was shown by Miller et  al. [2] in their clas-
sic Nature papers on the subject in 1975–1976 [1]. Their 
data showed that  Ca2+-ATPase in the oviduct positively 
correlated with shell thickness. Whereas the shell gland 
 Ca2+-ATPase activity was not particularly higher than 
in liver or kidney, it was far more sensitive to DDE. They 
found a cause-and-effect relationship strongly suggesting 
that DDE inhibited duck shell gland  Ca2+-ATPase. Spe-
cies sensitivity varies widely, but this work was a hallmark 
for in depth physiological and endocrinological under-
standing of the underlying causes of this environmental 
tragedy.
David was involved in eight more papers focused on 
studying the effects of ingesting small amounts of crude 
oil on key physiological processes in sea birds [14–21]. 
At the time, it was well-known that crude oil affects the 
ability of sea birds to fly, and as they preen to remove it, 
ingest the oil coating their feathers, thus exposing the 
digestive tract, liver, and kidney to potential damage due 
to dehydration and metabolic imbalance.
David, as part of the Kinter and Peakall collaboration, 
used gull (Larus argentatus) as a model to study crude 
oil toxicity in sea birds. While it was known that crude 
oil spills caused acute toxicity and death of waterfowl, 
the effects of small amounts of ingested crude oil as a 
result of preening could now be tested revealing effects 
on long-term survival and potential for ultimate lethality. 
Again, there was a heavy emphasis on intestinal trans-
port and  Na+/K+-ATPase activity in the nasal salt gland. 
The work showed definitively that small dose exposure to 
crude oil through ingestion by sea birds produced multi-
ple sublethal disruptions of metabolism and osmoregula-
tory capacity.
Since crude oil is a complex mixture of substances 
from potential endocrine disruptors to heavy metals 
[18], David transitioned to model substrates and trans-
port models to better define the mechanisms of toxic-
ity of specific substances. Chuck Holiday and others 
worked with David to develop the crab urinary blad-
der as a model to examine the mechanism of organic 
anion transport and later organic cation transport [16, 
22–27]. In a series of papers, they showed an inwardly 
directed, sodium-dependent (indirect) organic anion 
pump on the serosal membrane, cellular accumulation, 
and a facilitated step at the luminal surface.
Another environmental toxin that drew David’s atten-
tion was mercury, the third most toxic and persistent 
environmental chemical hazard. The oceans are the 
major source of the most toxic form of mercury, methyl 
mercury, and David exploited several marine physiolog-
ical models to start defining the mechanism of toxicity, 
especially related to epithelial transport [6, 28, 29]. He 
showed that a low concentration of mercury reduced 
organic anion transport in flounder renal tubule by 
both inhibiting  Na+/K+-ATPase and increasing mem-
brane ionic permeability.
In summary, David’s early work greatly increased our 
understanding of epithelial organic anion and cation 
transport processes and mechanisms of toxicity of envi-
ronmental hazards.
Postdoctoral years at  the  Mount Desert Island Biologi‑
cal Laboratory Notes from Karl Karnaky, Jr.: I first met 
David when he joined Dr. Kinter’s group as a Postdoc-
toral Research Associate at the Mount Desert Island 
Biological Laboratory (MDIBL) in Salsbury Cove in 
the summer of 1973, shortly after he had completed 
his Ph.D. in Biochemistry at the University of Maine in 
Orono. In what would be a harbinger of the publication 
rate he achieved during his career; David had already 
published five papers when he arrived at MDIBL [30–
34]. I had not known David more than 2 min when he 
told me his middle initial, “S”, stood for “Superb”. That 
was my introduction to David’s humorous side, which I 
have enjoyed all these years. We have been sharing and 
still are sharing a ton of jokes up until this present day. 
This “superb” label turned out to be prophetic as David 
published a long list of important papers.
During David’s 3  years as a postdoctoral research 
associate, I was able to interact with him on a daily 
basis. Although most of David’s research interests 
during my postdoctoral years at MDIBL (1972–1976) 
were different from mine, I did get the chance to col-
laborate with him and Larry Renfro on a study in which 
we localized the critical transporting enzyme,  Na+/
K+-ATPase, in winter flounder urinary bladder using 
3H-ouabain autoradiography. During the very rough 
draft stage of writing, one of the three authors submit-
ted a very long paragraph that lumbered and collapsed 
of its own accord. David wrote next to the paragraph 
the phrase: “E pluribus unum” (“One out of many”).
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The specific projects that David worked on start-
ing as a postdoctoral fellow focused on transport pro-
cesses, the cause of eggshell thinning, and the effects 
of various xenobiotic molecules on biological pro-
cesses. David started this long list of publications with 
a 1975 paper in Nature [1]. This study focused on pro-
longed eggshell thinning caused by DDE in the duck. It 
was the start of a productive collaboration with David 
Peakall and William B. Kinter.
I left MDIBL for my first position at Temple Medi-
cal School in Philadelphia in September 1976 but came 
back for summer research until 1980. By that time, I 
was working on a separate project and did not collabo-
rate with David. I returned to summer research in 1989 
with a Markey Foundation Grant from MDIBL and 
was able to return for summer research there a num-
ber of years until 2002 with the help of the Salsbury 
Cove Research Fund. By this time, David was deeply 
involved in organic anion secretion processes and was 
utilizing the powerful tool of the confocal fluores-
cence microscope. This instrument could detect and 
help quantify transport of fluorescent xenobiotic mol-
ecules and David was a master at extracting data from 
biological tissues with this device. David, Rosalinde 
Masereeuw, John Henson, and I exploited this tech-
nique to detect the excretory transport of xenobiotics 
by dogfish shark rectal gland tubules [5]. We contin-
ued our studies of the shark rectal gland tubules with a 
paper on the regulation of a specific xenobiotic trans-
porter, MRP2 [35]. During some of these summers, 
we also examined xenobiotic transporter activity in 
cricket Malpighian tubules. These studies culminated 
in a review article entitled “The xenobiotic transporter, 
MRP2, in epithelia from insects, sharks, and the human 
breast: implications for health and disease” [36]. We 
found that Mrp2 is present at the apical membrane of 
human breast ductules suggesting that Mrp2 trans-
ports carcinogens into the lumens of these ductules. 
Collaborating with David helped me develop some of 
my ideas and consequently secure several grants on 
this topic. In 2001, I invited David to give the key-
note speech at an annual mini symposium, “Epithelial 
metabolism and transport of xenobiotic and endog‑
enous molecules” that I organized in my Cell Biology 
and Anatomy Department at the Medical University of 
South Carolina.
Together, in the years from 1975 to the mid-1990s, 
David focused his research on excretory transport of 
xenobiotics in kidney, intestine, and urinary bladder of 
various animal models. During that time, David worked 
with numerous collaborators including Peakall, Kinter, 
Guarino, Pritchard, Holliday, Hallett, Barnes, and oth-
ers including myself.
The 1990s to The Millennium: head of the Intracellular 
Regulation Group at NIEHS
Studying renal organic anion and  cation uptake Notes 
from Rosalinde Masereeuw and Gert Fricker: In the 1990s, 
David’s research was focused on transport processes in 
the kidney, and he was one of the first researchers com-
bining functional and mechanistic aspects of transport 
processes in intact kidney tubules [26, 37]. Kidney tubule 
secretion appeared to be a two-step process mediated by 
carrier proteins on basolateral plasma membranes of the 
tubular epithelium and the luminal membranes. In addi-
tion, David showed that metabolic energy is required to 
pump organic cations across a cellular membrane against 
an electrochemical gradient—a landmark in transporter 
research. Using renal tubules from Southern flounder 
and killifish, David, John Pritchard and colleagues elu-
cidated the relationship between organic cation uptake 
and basolateral membrane potential [38]. These studies 
were extended to organic anions in crab urinary bladder, 
which has a simple, flat-sheet epithelium that is structur-
ally and functionally similar to vertebrate renal proximal 
tubule [27]. Subsequently, David and colleagues con-
ducted experiments with isolated basolateral (BLM) and 
brush-border membrane (BBM) vesicles, both exhibit-
ing  Li+-sensitive,  Na+-coupled glutarate uptake [39]. As 
in vertebrate renal proximal tubule, p-aminohippurate 
(PAH) was driven by exchange with (α-keto-)glutarate in 
bladder BLM. However, indirect coupling to  Na+ could 
potentially also drive uphill PAH transport in intact epi-
thelium. To study the role of this mechanism in net tran-
sepithelial PAH secretion, David and John Pritchard used 
renal proximal tubules from Southern flounder [40]. They 
found that tubules exhibited both  Na+/glutarate uptake 
and  glutarate+/PAH exchange. To determine if indirect 
coupling affected net secretion and tissue accumulation, 
David and John Pritchard measured the steady-state accu-
mulation of the anionic fluorescent dye, fluorescein (FL), 
and demonstrated that glutarate stimulated uphill FL entry 
into tubular cells and also stimulated active FL secretion 
into the tubular lumen. Based on this observation David 
concluded that FL follows the route of PAH transport. It is 
worth noting that David used epifluorescence microscopy 
and video-image analysis for these studies, which became 
instrumental in David’s future work.
To investigate intracellular sequestration of organic 
anions, David and colleagues studied the distribution 
of FL in crab urinary bladder, cultured opossum kidney 
cells, and intact killifish (Fundulus heteroclitus) proximal 
tubules (Fig. 2; [41–43]). At that time, I, Rosalinde Maser-
eeuw, was a Ph.D. student at Radboud Universitiy Medi-
cal Center in Nijmegen, the Netherlands and contacted 
David to spend time in his laboratory. My observations 
of FL accumulation in rat kidney proximal tubule cells 
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contradicted his observations in other models; we solved 
this collaboratively [44].
Moving to  apical transporters in  the  kidney In 1994, 
David and I, Gert Fricker, University of Heidelberg, Ger-
many, had a unique opportunity: we received a fluores-
cent derivative of the immunosuppressant cyclosporin 
A, NBD-cyclosporin A (NBD-CSA), that was custom-
synthesized by Dr. Roland Wenger, Sandoz Pharma AG, 
Basel, Switzerland. The experiments that followed were 
the beginning of a long-lasting series of studies that con-
tinue until today. NBD-CSA turned out to be the ideal tool 
to visualize transport mediated by P-glycoprotein (P-gp), 
an ABC efflux transporter that had shortly prior been 
identified to transport cyclosporin A. In joint studies at 
the MDIBL, David, Gert Fricker and colleagues measured 
NBD-CSA transport in killifish proximal tubules [45] and 
observed that NBD-CSA accumulation in tubular lumens 
was time-dependent, saturable, and in steady-state, 
NBD-CSA fluorescence intensity in tubular lumens was 
2–3 times higher than fluorescence in renal cells, which 
appeared to be due to P-gp.
Furthermore, we investigated the renal excretion of a 
fluorescent rapamycin derivative in isolated killifish kid-
ney tubules [46, 47]. We found that excretion into the 
tubular lumen was blocked by metabolic inhibitors and 
P-gp substrates, and unlabelled rapamycin blocked P-gp-
mediated secretion of NBD-CSA. We later made similar 
observations in killifish tubules with HIV protease inhibi-
tors [48] and the somatostatin analogue octreotide [49, 
50].
David observed this phenomenon for daunomycin in 
killifish renal proximal tubules [51]. At pH 8.25, dauno-
mycin crossed the basolateral membrane of tubules by 
simple diffusion and was then secreted into the tubular 
lumen by P-gp. At pH 7.25, daunomycin was transported 
across the basolateral membrane by organic cation trans-
porter-mediated uptake and simple diffusion, and was 
secreted into the lumen by P-gp and the organic cation/
H+ exchanger, which was most likely what was later iden-
tified as the Multidrug and Toxin Extrusion proteins, 
MATE1 and MATE2-K.
With Jim Boyer, Yale Medical School, New Haven, CT, 
David also studied isolated hepatocytes from the marine 
Fig. 2 Killifish. a Killifish (Fundulus heteroclitus). b Transmitted light image of an intact killifish tubule. c Confocal image showing a killifish renal 
proximal tubule stained for Mrp2; [63]. From the Journal of Pharmacology and Experimental Therapeutics with permission. d Confocal image 
showing accumulation of fluorescein‑methotrexate (FL‑MTX) in the lumen of a killifish renal proximal tubule [58]
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vertebrate Raja erinacea (little skate; [52]). Using confo-
cal fluorescence microscopy, David and colleagues elu-
cidated the cellular organization of actin filaments and 
observed that nocodazole disrupted transcytosis of a 
fluorescent bile salt derivative into canalicular lumens. 
The polarized arrangement of microtubules, the find-
ing of cytoplasmic dynein, and the inhibition of bile salt 
secretion by nocodozole were all consistent with the 
microtubule cytoskeleton playing a fundamental role in 
mediating endocytosis, transcytosis, and biliary excretion 
in these hepatocytes.
In skate hepatocyte clusters, David, Gert Fricker and 
colleagues also found that the microtubular network 
was involved in the secretion of the fluorescent bile salt 
derivative NBD-taurocholate (NBD-TC; [53]). NBD-
TC uptake by skate hepatocytes appeared to be active, 
but not dependent on the membrane potential or  Na+, 
whereas its secretion into canaliculi was driven, at least 
partially, by the membrane potential and was depended 
on intact microtubules.
Transport of organic anions remained David’s research 
focus. Using FL, carboxyfluorescein diacetate and 
bimane-S conjugates, he showed that organic anion 
excretion in killifish tubules is carrier-mediated and 
against the concentration gradient but not sensitive to 
the electrical potential difference across the luminal 
membrane [54]. By this time, we had discovered an addi-
tional transport route for organic anions that was distinct 
from PAH and FL. Using killifish renal proximal tubules 
and the larger organic anion, fluorescein methotrex-
ate (FL-MTX, 923  Da), we observed  Na+-independent 
influx and active luminal secretion that mimicked the 
recently identified multidrug resistance-associated pro-
tein, MRP2, another ATP-driven ABC efflux transporter 
(Fig.  2d). Using immunostaining, we confirmed Mrp2 
expression at the luminal membrane of killifish tubules 
[55]. A similar transport system also appeared to be pre-
sent in dogfish shark (Squalus acanthias) rectal gland, 
which is a specialized, osmoregulatory organ composed 
of numerous blind-ended, branched tubules emptying 
into a central duct [56].
In 1998, David published a key observation made in 
killifish tubules, which became important for our future 
studies on transporter regulation and signaling: Protein 
kinase C (PKC) regulation of organic anion transport 
suggesting direct or indirect regulation of organic anion 
transport at the basolateral membrane [5]. In addition, 
active excretion of daunomycin and NBD-CSA in kil-
lifish renal proximal tubules and monolayers of primary 
flounder kidney cells was affected by PKC activators 
and inhibitors indicating that P-gp-mediated xenobiotic 
secretion negatively correlates with PKC activity [57].
For our studies, isolated killifish proximal tubules 
represented a unique model to study the regulation of 
transporters, in particular MRP2 and P-gp. Over several 
summers at the MDIBL (1998–2005), we used FL-MTX 
and NBD-CSA to investigate the role of the vasoactive 
peptide endothelin-1 (ET-1) on the functional expression 
of the efflux pumps P-gp and Mrp2 [58–62]. The ET-1 
effect on P-gp and Mrp2 was mediated by ET-1 activation 
of the ET(B) receptor followed by downstream signaling 
involving PKC, PKA, and nitric oxide (NO). Exposing 
renal tubules to nephrotoxicants resulted in the genera-
tion of NO and upregulation of the efflux pumps, which 
likely has a nephroprotective effect through mediat-
ing the excretion of harmful xenobiotics. We made this 
observation after short-term exposure as well as after 
longer-term exposures [63]. These findings suggested 
involvement of genomic as well as post-translational 
regulation of the efflux pumps in killifish kidney tubules, 
which was confirmed for Mrp2 several years later [64].
From kidney tubules to  choroid plexus and  brain capil‑
laries In 1999, David switched from liver and kidney 
to choroid plexus, an organ which is often referred to as 
the “kidney in the brain” due to its functional similarity 
to renal tissue. Together with Alice Villalobos and John 
Pritchard, David studied uptake and distribution of the 
fluorescent organic cation quinacrine in primary cultures 
of rat choroid plexus epithelial cells [65] and in intact 
choroid plexus tissue from cow [66]. Since the rat renal 
exchanger (rROAT1) was cloned together with Douglas 
Sweet and John Pritchard, [67], a rROAT1-green fluores-
cent protein construct was used to analyze the protein 
distribution directly in transiently transfected rat choroid 
plexus. Consistent with the functional studies, the GFP-
tagged transporter was detected in apical but not basolat-
eral membranes of the choroid plexus.
Looking back on the transporter field of the 1990s, 
David’s work had an enormous impact both on our 
understanding of mechanisms underlying renal function 
as well as on the development of novel tools to investigate 
transport phenomena in the kidney. The combination of 
confocal laser scanning microscopy and isolated intact 
kidney tubules offered completely new perspectives to 
investigate transport in an experimental ex  vivo system 
that was closer to the in vivo situation as any other model 
used before. Thus, it was only natural to apply these 
approaches for other tissues, e.g., the choroid plexus and 
the blood–brain barrier, as well. In 2000, David and col-
leagues published the first paper identifying transporters 
and studying their function in isolated pig brain capillar-
ies [68]. These results validated a new method of studying 
drug transport in isolated brain capillaries and implied 
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that both P-gp and Mrp family members are involved in 
drug transport at the blood–brain barrier.
The 2000s until 2010
Notes from Anika Hartz and Björn Bauer: Before the year 
2000, David’s work was primarily focused on renal trans-
port, but he also had some collaborations studying the 
choroid plexus (the “kidney in the brain”). Starting in the 
late 1990s, David’s interest and excitement shifted toward 
transporters at the blood–brain barrier, which remained 
his main research focus until his retirement. The first 
studies evolved around xenobiotic transport in isolated 
brain microvessels from killifish using live imaging and 
confocal microscopy, David’s favorite and most powerful 
instrument in the laboratory [35, 68, 69].
In July 2002, we—Bjoern Bauer and Anika Hartz—
arrived at Raleigh-Durham International airport in North 
Carolina, where John Pritchard picked us up since David 
had already left for Maine. After settling in our new home 
and lab at the NIEHS, we joined David at the MDIBL for 
the rest of the summer working on ET-1-mediated regu-
lation of Mrp2 in isolated killifish brain capillaries. After 
returning to North Carolina, our first charge in David’s 
laboratory was to establish a brain capillary isolation pro-
tocol for rodents. With this protocol in place, we began 
translating some of David’s previous work in fish and 
other species into isolated rat brain capillaries. This was 
the start of a series of studies investigating signaling path-
ways that regulate blood–brain barrier ABC transporters 
such as P-gp, BCRP and Mrp2 (Fig.  3). The first study 
closely followed the discoveries made by David et  al. in 
kidney tubules showing that the hormone endothelin-1 
(ET-1) regulates P-gp transport activity in isolated brain 
capillaries [70]. In parallel, Bjoern convinced David to 
look into nuclear receptor regulation of ABC transport-
ers, an idea that was sparked by a seminar Ronald Evans, 
the father of nuclear receptors, held at the MDIBL that 
Bjoern had attended in July 2001. We found that the 
pregnane X receptor (PXR) is expressed at the blood–
brain barrier where it regulates P-gp protein expression 
and transport function [71–73]. These initial studies built 
the framework for many following studies. Along the way 
we discovered that the inflammatory mediators, TNF-α 
and ET-1, regulate P-gp in a time-dependent and con-
centration-dependent manner—a finding David labeled 
as “context-dependent regulation” [74]. Based on these 
findings, David hypothesized that targeting inflammatory 
signaling in CNS pathologies could have a potential ther-
apeutic benefit, which would prove correct in our later 
work and is still valid and part of our research to this day.
Around the same time, David started a collaboration 
with John Hong’s group at the NIEHS, expanding our 
inflammation studies to an environmental toxin—diesel 
exhaust. We found that diesel exhaust particles induce 
oxidative stress and pro-inflammatory signaling that up-
regulates P-gp at the blood–brain barrier [75]. In 2005, 
David had a discussion with us that would prove to be 
critical for our careers: he pointed out that in order to 
be successful in securing NIH funding, we would have to 
start thinking about connecting our interests in blood–
brain barrier transporter regulation to CNS disease. This 
prompted Bjoern to explore the mechanism underly-
ing transporter regulation at the blood–brain barrier 
in epilepsy, an idea based on published work [76] and a 
5 μm5 μm
a b 
Fig. 3 Brain capillary model. a Transmitted light image of an isolated rat brain capillary. b Confocal image of an isolated rat brain capillary 
immunostained for P‑glycoprotein (green, nuclei counterstained with propidium iodide in red; [103]. From Pharmacological Reviews with 
permission
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seminar highlighting the role of glutamate in epilepsy. 
David invited Heidrun Potschka, an expert in animal sei-
zure models, to visit the NIEHS in 2005. A first combined 
ex vivo/in vivo study followed that focused on a signaling 
pathway through which seizures up-regulate P-gp expres-
sion at the blood–brain barrier [77]. Based on our previ-
ous work studying the effect of inflammatory markers on 
transporters [70, 74], David suggested early on in the pro-
ject that we also look into COX-2-mediated inflamma-
tion in epilepsy. Indeed, our data suggested that COX-2 
inhibition may be one way to improve the response to 
antiepileptic drugs, a concept that was exciting to all of 
us. Several more publications around this topic followed 
[77–79] and this line of research eventually translated 
into Bjoern’s research program that is an active project in 
our laboratory to this day [80–82].
In 2005, one publication—Cirrito et  al. [83]—raised 
David’s interest. In combination with the paper by Lam 
et  al. [84] this work suggested that blood–brain barrier 
P-gp transports Aβ, a neurotoxin that accumulates in 
Alzheimer’s disease [83, 84]. David became curious and 
wanted to find out if we could follow P-gp-mediated 
Aβ transport in isolated brain capillaries. David’s initial 
experiments using confocal microscopy and fluorescent-
labeled Aβ40 did not seem to work. While he lost interest, 
Anika decided to give the assay another try. By simply 
switching from Aβ40 to Aβ42, she made the assay work 
in isolated rat brain capillaries and brought back David’s 
interest. We later learned that Aβ40 triggers a signaling 
pathway that reduces P-gp transport activity explain-
ing why David’s initial experiments “did not work” [85, 
86]. This project developed into Anika’s current research 
program.
In a project focusing on another ABC transporter—
breast cancer resistance protein, BCRP (ABCG2)—we 
unraveled an estrogen signaling pathway through which 
17β-estradiol (E2) downregulates BCRP, another critical 
ABC efflux transporter at the blood–brain barrier [87, 
88]. We found that E2 signals through ERbeta, PTEN/
PI3K/Akt/GSK3 leading to proteasomal degradation of 
BCRP. Later we discovered that intervention with this 
pathway downregulates both BCRP and P-gp, which is 
a strategy we currently test in our laboratory to increase 
brain uptake of chemotherapeutic drugs in brain cancer.
Looking back, long days in David’s laboratory were bro-
ken up by group lunches and birthday celebrations with 
food and cake organized by postdocs and students. David 
enjoyed these social events and used them as an oppor-
tunity to connect with lab members to talk about science 
and more. David loved to be part of these events, but he 
never wanted to be the center of attention.
Weekly lab meetings were held jointly between our 
and John’s group. In fact, we were functioning as one 
big group with the luxury of having two fantastic men-
tors. In 2004, John Pritchard won the “NIEHS Mentor of 
the Year” award; David received the award in 2006. This 
award is presented by the NIEHS Trainees Assembly 
and honors an NIEHS scientist who has made a major 
impact both scientifically and personally in the training 
of fellows and students. This achievement highlights John 
and David as mentors. In the nurturing environment that 
John and David created, we made many fond memories. 
Trainees from David’s and John’s laboratories found jobs 
around the world and while we now live far apart from 
each other and are busy with our lives, we are all still con-
nected, we talk and meet from time to time and some of 
us even collaborate.
During the time we were in David’s laboratory 2002–
2007, David spent his summers at the MDIBL in Sals-
bury Cove in Maine, where we occasionally visited him 
to discuss data, projects and ideas. Dusty (Destiny Sykes), 
David’s research technician of almost 30  years, was his 
right and left hand in the laboratory and spent weeks of 
packing and shipping material and equipment to Maine 
each summer. Dusty was critical for David’s laboratory 
in many ways: she was the heart and soul of the lab and 
took the lead on David’s “crazy idea experiments” that he 
wanted to pursue. Dusty also helped new postdocs from 
all parts of the world feel welcome and at home, helped 
them get acquainted with daily life in the lab, and she 
provided critical input for the perfect Thanksgiving din-
ner for us foreigners.
Outside of the laboratory, David and his wife Mimi 
are avid horseback riders. They spent their weekends at 
the J&H Staples in Raleigh, North Carolina, where they 
boarded their horses. Both helped around the barn: they 
took care of the horses, cleaned the barn, enjoyed helping 
kids getting ready for their riding lessons, and watched 
and socialized with their parents during lessons. David 
and Mimi also took their horses out for long rides around 
the barn and to weekend-long riding through to nearby 
Virginia. They even convinced us to take up riding, which 
created a nice balance to the work in the laboratory. We 
left the NIEHS in July 2007 to take on faculty positions 
but kept collaborating with David on various projects 
while establishing our own laboratories. David hired 
highly productive postdocs who made significant scien-
tific contributions in linking changes in blood–brain bar-
rier and choroid-plexus transport to specific pathologies 
and xenobiotic exposures [89–96].
2010 until 2015
Notes from Ron Cannon: One late afternoon while work-
ing on the confocal microscope, I—Staff Scientist in the 
laboratory of Raymond Tennant at the NIEHS—hap-
pened to meet David while I was trying to localize a 
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newly discovered transporter, ABCA13, using immuno-
histochemistry. David was working on the confocal and 
was immediately interested in my findings. We talked for 
about an hour as he assisted me with the appropriate con-
focal settings to optimize my results. Within 6  months 
Raymond Tennant retired and David approached me 
with a request to join his laboratory. I gladly accepted 
and I worked with David until his departure in 2015. The 
work with David was most enjoyable and productive. 
David was driven by his passion for science. Numerous 
nights we discussed science by phone and continued the 
following morning. It was never a question of finding a 
project. The office and late-night discussions filled the 
project black board in his office. There was never a ques-
tion of “do we have a scientific project to study?” It was 
only a question of “which one”.
Most of David’s previous transporter work was focused 
on the blood–brain barrier transporter P-glycoprotein 
and how xenobiotic molecules modulated its activity. 
We decided to study how endogenous molecules might 
regulate ABC transporters like P-glycoprotein since 
that could be a better and more natural way in terms of 
treatment. We focused on how sphingolipids and cera-
mides regulate P-glycoprotein [97, 98]. Work in the lab 
progressed and we unraveled how sphingosine-1 phos-
phate and ceramide-1 phosphate regulate P-glycoprotein 
[97]. We later found that the S1P regulatory pathway 
was regulated upstream by a previously described TNF-
alpha pathway [99]. This work led to the finding that 
ceramide-1 phosphate induces P-glycoprotein transport 
activity. Moreover, this work helped conceptualize that 
ABC transporters may be dynamically controlled at the 
activity level without the need for changes in expression 
[100–102]. Figure 4 highlights David’s work on the regu-
lation of ABC transporters at the blood–brain barrier.
David’s departure and retirement from the NIEHS
David suffered a stroke in July 2015 and officially retired 
in early 2016 after more than 30 years of research at the 
NIEHS. He was well-known and liked by everyone. He 
loved scientific research; it was his passion. He men-
tored numerous students, post bac and post docs inside 
and outside of his lab. All of whom still call or sometime 
visit the laboratory. As I came to know him personally, I 
discovered his love for boating and horses. He would fly 
in lobsters from Maine to North Carolina for the yearly 
Lobster Fest at the barn where he boarded his horses. 
Then he would cook them in large pots as everyone anx-
iously awaited. He was kind and fair to everyone, no mat-
ter what their “walk” in life. Now as I walk the halls of 
NIEHS to attend meetings or lunch in the cafeteria, two 
questions and one statement are made by those who 
approach: “Have you talked to Dave lately? How is he 
doing? Tell him I asked about him and tell him we really 
miss him”. I think this says it all.
Beyond the science
Outstanding science can be summarized in a review arti-
cle. We want this tribute to David to be more than a sum-
mary of professional accomplishments. The following 
personal memories, thoughts and thank you notes high-
light what makes David special to us as a scientist, men-
tor, and friend.
Larry Renfro: “Science aside, perhaps David’s most 
important contribution is his continuing good-natured 
irascibility, matter-of-fact no-nonsense approach to sci‑
ence, and contagious enthusiasm. Thank you, David, for 
all your help.”
Karl Karnaky: “Of all the people one meets in life only a 
few are really special. For me, David is one of these people 
– not only for the rewarding scientific interactions but also 
on a human interaction level. There were two enormous 
emotional situations, one for David and one for me, in 
which we helped each other immensely. Fortunately, our 
interactions continue as David and Mimi moved to Ells‑
worth in 2016. For about nine years now, I have been com‑
ing to Bar Harbor, about 25  min away, and we are able 
to have breakfast once a week while I am here. I related 
several humorous stories in the text above, but I am so 
glad to be able to see David for a good portion of the year 
now. After knowing David for 45 years I still see why he is 
“superb”.
Rosalinde Masereeuw: “I arrived in David’s lab in Feb‑
ruary 1995 as a Ph.D. student from the Netherlands who 
was awarded a fellowship for an international training. 
I could not have made a better choice in selecting a lab. 
David was the best mentor ever: he would patiently sit 
down with me to draw a serious research plan, in his own 
way with lots of jokes in between. His curiosity and enthu‑
siasm was a driver in our collaborative work. He also 
showed how to balance between a work life and a private 
life. For me, he was the example of how to be a scientist 
and a mentor myself. Thank you, David!”
Gert Fricker: “I first met David 30  years ago at the 
MDIBL and for me it was one of the most important 
encounters in my life. His outstanding ability to explain 
scientific coherencies together with his most helpful and 
patient personal attitude made him an ideal mentor and 
very good friend for me. David, thank you for all.”
Anika Hartz: “David infected me with his contagious 
enthusiasm for science. David’s assurance, continuous 
mentoring and his love and passion for science convinced 
me that science is the best. David introduced to me the 
concept of “thinking outside the box” by showing me the 
box I was trapped in – a game changer for me and most 
other trainees that listened carefully what he said. To 
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complex questions David had a simple answer: “Do the 
right thing” – this could mean to repeat a time-consum‑
ing experiment, rewrite a manuscript or simply help a 
newcomer in the lab. What it gave me as a trainee was 
guidance, professionalism and a simple rule applicable to 
science and life in general. David: Thank you for doing the 
right thing!”
Björn Bauer: “My time in David’s lab was invalu‑
able. David had the patience to listen and always gave 
honest feedback: he told me the things I needed to hear, 
not the things I wanted to hear. To me, one of the most 
memorable things David said was when he received the 
NIEHS Mentor of the Year Award. David said: “I can’t 
believe they let me play in the sandbox and even pay me 
for this!”. Thank you, David, for the unforgettable experi‑
ence. Your advice resonates with me to this day!”
Ron Cannon: “As I reflect on my years of working with 
David, I recognize his greatest ability was to lead with 
passion. His excitement for every project in the lab was 
infectious. His wide smile as new and interesting data 
arrived was genuine and motivating. And rather than 
sit alone and ponder new data, David preferred open 
engagement and discussions. He urged us to think‑
ing deeply about our work and to consider its meaning 
and implications. What a great life lesson! Thank you, 
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David, for being a good friend, a great colleague, and 
teaching us how to enjoy science to its fullest!”
John Pritchard: “David and I first met almost 50 years 
ago, when he was still a graduate student with Lerner in 
Orono and I was a post doc in Bill Kinter’s laboratory at 
MDIBL. We have worked together on and off ever since. 
We both gained a solid grounding in renal physiology, 
the comparative method, and a mechanistic approach to 
environmental issues with Bill. I subsequently focused on 
isolated membrane vesicles and molecular tools, while 
David developed confocal and fluorescence microscopy 
approaches. Together we collaborated on studies of renal 
function and mechanisms of environmental toxicity over 
many of those 50  years. Not only did our scientific tools 
complement each other, but our work styles were simi‑
larly complementary. I was the more systematic, whereas 
David was more free ranging, ensuring that we looked at 
all the possibilities. It was a good run, and a fun one as 
well. I count myself as extremely fortunate to have had 
such a good friend and colleague.
Finally, I note that our lives have continued to parallel 
each other in recent years. David had his stroke and I, my 
cervical spinal injury. Happily, we have both made con‑
siderable progress in establishing a new normal, one that 
we continue to refine.”
David S. Miller Young Scientist Award—honoring David’s 
mentorship for years to come
The “David S. Miller Young Scientist Award” was initiated 
in 2016 to honor David as a mentor, as a scientist, and as 
a friend. David had a positive impact on the career and 
life of numerous students and postdocs. He encouraged 
young scientists to think outside the box, sparked their 
interest in research, gave them valuable insights into 
the world of science, and guided each student along the 
way. The “David S. Miller Young Scientist Award” honors 
David’s mentorship by supporting young scientists with 
promising research in the brain barriers research field.
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